Posted by Michael Wonder on 25 Jul 2021
EMA CHMP adopts positive opinion recommending authorisation for the use of the Moderna COVID-19 Vaccine in adolescents (12-17 years of age) in the European Union
23 July 2021 - . 23, 2021-- Moderna today announced that the EMA's CHMP adopted a positive opinion recommending marketing authorisation for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older.
Spikevax is the trade name authorised by the EMA for the Moderna COVID-19 vaccine.
